{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:36:53Z","timestamp":1753439813524},"reference-count":37,"publisher":"Pharmaceutical Society of Japan","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2022,4,1]]},"DOI":"10.1248\/bpb.b21-00860","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T22:12:46Z","timestamp":1648764766000},"page":"452-459","source":"Crossref","is-referenced-by-count":2,"title":["Risk Assessment of Neutropenia during Low-Dose Valganciclovir Prophylaxis for Heart Transplant Recipients"],"prefix":"10.1248","volume":"45","author":[{"given":"Mai","family":"Otokubo","sequence":"first","affiliation":[{"name":"Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoichi","family":"Wada","sequence":"additional","affiliation":[{"name":"Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Ikura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotoka","family":"Hayase","sequence":"additional","affiliation":[{"name":"Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takaya","family":"Uno","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Nakagita","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Hayakawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Seguchi","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihide","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Department of Transplant Medicine, National Cerebral and Cardiovascular Center"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Education and Research Center for Clinical Pharmacy, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Fukushima N, Ono M, Saiki Y, Sawa Y, Nunoda S, Isobe M. Registry report on heart transplantation in Japan (June 2016). Circ. J.<\/i>, 81<\/b>, 298\u2013303 (2017).","DOI":"10.1253\/circj.CJ-16-0976"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Petrakopoulou P, K\u00fcbrich M, Pehlivanli S, Meiser B, Reichart B, von Scheidt W, Weis M. Cytomegalovirus infection in heart transplant recipients is associated with impaired endothelial function. Circulation<\/i>, 110<\/b> (Suppl. 1), II207\u2013II212 (2004).","DOI":"10.1161\/01.CIR.0000138393.99310.1c"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA<\/i>, 261<\/b>, 3561\u20133566 (1989).","DOI":"10.1001\/jama.261.24.3561"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation<\/i>, 76<\/b>, 1470\u20131474 (2003).","DOI":"10.1097\/01.TP.0000090163.48433.48"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Johansson I, Andersson R, Friman V, Selimovic N, Hanzen L, Nasic S, Nystr\u00f6m U, Sigurdardottir V. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients. BMC Infect. Dis.<\/i>, 15<\/b>, 582 (2015).","DOI":"10.1186\/s12879-015-1321-1"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Suarez-Pierre A, Giuliano K, Lui C, Almaguer D, Etchill E, Choi CW, Kilic A, Higgins RS. Impact of cytomegalovirus serologic status on heart transplantation. J. Card. Surg.<\/i>, 35<\/b>, 1431\u20131438 (2020).","DOI":"10.1111\/jocs.14588"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, Humar A. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation<\/i>, 102<\/b>, 900\u2013931 (2018).","DOI":"10.1097\/TP.0000000000002191"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant.<\/i>, 33<\/b>, e13512 (2019).","DOI":"10.1111\/ctr.13512"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Khalil MAM, Khalil MAU, Khan TFT, Tan J. Drug-induced hematological cytopenia in kidney transplantation and the challenges it poses for kidney transplant physicians. J. Transplant.<\/i>, 2018<\/b>, 9429265 (2018).","DOI":"10.1155\/2018\/9429265"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Echenique IA, Angarone MP, Rich JD, Anderson AS, Stosor V. Cytomegalovirus infection in heart transplantation: a single center experience. Transpl. Infect. Dis.<\/i>, 20<\/b>, e12896 (2018).","DOI":"10.1111\/tid.12896"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Imlay H, Dumitriu Carcoana AO, Fisher CE, Wong B, Rakita RM, Fishbein DP, Limaye AP. Impact of valganciclovir prophylaxis duration on cytomegalovirus disease in high-risk donor seropositive\/recipient seronegative heart transplant recipients. Transpl. Infect. Dis.<\/i>, 22<\/b>, e13255 (2020).","DOI":"10.1111\/tid.13255"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Kalil AC, Freifeld AG, Lyden ER, Stoner JA. Valganciclovir for cytomegalovirus prevention in solid organ transplant patients: an evidence-based reassessment of safety and efficacy. PLoS ONE<\/i>, 4<\/b>, e5512 (2009).","DOI":"10.1371\/journal.pone.0005512"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Stevens DR, Sawinski D, Blumberg E, Galanakis N, Bloom RD, Trofe-Clark J. Increased risk of breakthrough infection among cytomegalovirus donor-positive\/recipient-negative kidney transplant recipients receiving lower-dose valganciclovir prophylaxis. Transpl. Infect. Dis.<\/i>, 17<\/b>, 163\u2013173 (2015).","DOI":"10.1111\/tid.12349"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimated GFR from serum creatinine in Japan. Am. J. Kidney Dis.<\/i>, 53<\/b>, 982\u2013992 (2009).","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Watanabe T, Yanase M, Seguchi O, et al.<\/i> Influence of induction therapy using basiliximab with delayed tacrolimus administration in heart transplant recipients\u2014comparison with standard tacrolimus-based triple immunosuppression. Circ. J.<\/i>, 84<\/b>, 2212\u20132223 (2020).","DOI":"10.1253\/circj.CJ-20-0164"},{"key":"16","unstructured":"16) Schimmer BP, Funder JW. Adrenocorticotropic hormone, adrenal steroids, and the adrenal cortex. Goodman & Gilman\u2019s the pharmacological basis of therapeutics<\/i>. (Brunton LL, Hilal-Dandan R, Knollmann BC eds.) 13th ed., McGraw-Hill Medical, New York, pp. 845\u2013861 (2018)."},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Chow JKL, Ruthazer R, Boucher HW, Vest AR, DeNofrio DM, Snydman DR. Factors associated with neutropenia post heart transplantation. Transpl. Infect. Dis.<\/i>, 23<\/b>, e13634 (2021).","DOI":"10.1111\/tid.13634"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Cooke ME, Potena L, Luikart H, Valantine HA. Peripheral blood leukocyte counts in cytomegalovirus infected heart transplant patients: impact of acute disease versus<\/i> subclinical infection. Transplantation<\/i>, 82<\/b>, 1419\u20131424 (2006).","DOI":"10.1097\/01.tp.0000242139.13197.7f"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Abbas F, El Kossi M, Shaheen IS, Sharma A, Halawa A. Drug-induced myelosuppression in kidney transplant patients. Exp. Clin. Transplant.<\/i>, 19<\/b>, 999\u20131013 (2021).","DOI":"10.6002\/ect.2020.0100"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Pazdernik M, Malek I, Koudelkova E, Sochman J, Kautzner J. Bone marrow suppression and associated consequences in patients after heart transplantation: a 6-year retrospective review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.<\/i>, 159<\/b>, 372\u2013377 (2015).","DOI":"10.5507\/bp.2015.022"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Amorim J, Costa E, Teixeira A, Rebocho MJ, Loureiro M, Barbot J. Tacrolimus-induced neutropenia in a cardiac transplant patient. Pediatr. Transplant.<\/i>, 18<\/b>, 120\u2013121 (2014).","DOI":"10.1111\/petr.12188"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Duggal T, Dempster M, Prashar R. Calcineurin inhibitors and neutropenia: Is cyclosporine superior to tacrolimus? Am. J. Case Rep.<\/i>, 20<\/b>, 1407\u20131410 (2019).","DOI":"10.12659\/AJCR.917282"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Dobrolet NC, Webber SA, Blatt J, Michaels M, Kiaffas M, Kurland G, Boyle GJ. Hematologic abnormalities in children and young adults receiving tacrolimus-based immunosuppression following cardiothoracic transplantation. Pediatr. Transplant.<\/i>, 5<\/b>, 125\u2013131 (2001).","DOI":"10.1034\/j.1399-3046.2001.00044.x"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) De Rycke A, Dierickx D, Kuypers DR. Tacrolimus-induced neutropenia in renal transplant recipients. Clin. J. Am. Soc. Nephrol.<\/i>, 6<\/b>, 690\u2013694 (2011).","DOI":"10.2215\/CJN.07320810"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Kovarik JM, Eisen H, Dorent R, Mancini D, Vigano M, Rouilly M, Hsu CH, Rordorf C. Everolimus in de novo<\/i> cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure. J. Heart Lung Transplant.<\/i>, 22<\/b>, 1117\u20131125 (2003).","DOI":"10.1016\/S1053-2498(02)01221-4"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Urbanowicz T, Straburzy\u0144ska-Migaj E, Klotzka A, Baszy\u0144ska-Wachowiak H, Misterski M, Grajek S, Jemielity M. Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. Ann. Transplant.<\/i>, 19<\/b>, 494\u2013498 (2014).","DOI":"10.12659\/AOT.890816"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Czock D, Scholle C, Rasche FM, Schaarschmidt D, Keller F. Pharmacokinetics of valganciclovir and ganciclovir in renal impairment. Clin. Pharmacol. Ther.<\/i>, 72<\/b>, 142\u2013150 (2002).","DOI":"10.1067\/mcp.2002.126306"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Perrottet N, Decosterd LA, Meylan P, Pascual M, Biollaz J, Buclin T. Valganciclovir in adult solid organ transplant recipients: pharmacokinetic and pharmacodynamic characteristics and clinical interpretation of plasma concentration measurements. Clin. Pharmacokinet.<\/i>, 48<\/b>, 399\u2013418 (2009).","DOI":"10.2165\/00003088-200948060-00006"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Liang X, Famure O, Li Y, Kim SJ. Incidence and risk factors for leukopenia in kidney transplant recipients receiving valganciclovir for cytomegalovirus prophylaxis. Prog. Transplant.<\/i>, 28<\/b>, 124\u2013133 (2018).","DOI":"10.1177\/1526924818765798"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Tomonari A, Iseki T, Takahashi S, Ooi J, Yamada T, Takasugi K, Nagamura F, Uchimaru K, Tojo A, Asano S. Ganciclovir-related neutropenia after preemptive therapy for cytomegalovirus infection: comparison between cord blood and bone marrow transplantation. Ann. Hematol.<\/i>, 83<\/b>, 573\u2013577 (2004).","DOI":"10.1007\/s00277-004-0887-2"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Molina Perez E, Fern\u00e1ndez Castroagud\u00edn J, Seijo R\u00edos S, Mera Calvi\u00f1o J, Tom\u00e9 Mart\u00ednez de Rituerto S, Otero Ant\u00f3n E, Bustamante Montalvo M, Varo Perez E. Valganciclovir-induced leukopenia in liver transplant recipients: influence of concomitant use of mycophenolate mofetil. Transplant. Proc.<\/i>, 41<\/b>, 1047\u20131049 (2009).","DOI":"10.1016\/j.transproceed.2009.02.033"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am. J. Kidney Dis.<\/i>, 45<\/b>, 804\u2013817 (2005).","DOI":"10.1053\/j.ajkd.2005.02.010"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Randhawa PS, Starzl TE, Demetris AJ. Tacrolimus (FK506)-associated renal pathology. Adv. Anat. Pathol.<\/i>, 4<\/b>, 265\u2013276 (1997).","DOI":"10.1097\/00125480-199707000-00032"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Hwang SD, Lee JH, Lee SW, Kim JK, Kim MJ, Song JH. Effect of low-dose vs.<\/i> standard-dose valganciclovir in the prevention of cytomegalovirus disease in kidney transplantation recipients: a systemic review and meta-analysis. Transplant. Proc.<\/i>, 50<\/b>, 2473\u20132478 (2018).","DOI":"10.1016\/j.transproceed.2018.01.023"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Venton G, Crocchiolo R, F\u00fcrst S, Granata A, Oudin C, Faucher C, Coso D, Bouabdallah R, Berger P, Vey N, Ladaique P, Chabannon C, le Merlin M, Blaise D, El-Cheikh J. Risk factors of ganciclovir-related neutropenia after allogeneic stem cell transplantation: a retrospective monocentre study on 547 patients. Clin. Microbiol. Infect.<\/i>, 20<\/b>, 160\u2013166 (2014).","DOI":"10.1111\/1469-0691.12222"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Matsumoto K, Shigemi A, Ikawa K, Kanazawa N, Fujisaki Y, Morikawa N, Takeda Y. Risk factors for ganciclovir-induced thrombocytopenia and leukopenia. Biol. Pharm. Bull.<\/i>, 38<\/b>, 235\u2013238 (2015).","DOI":"10.1248\/bpb.b14-00588"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Chen IM, Chang HH, Hsu CP, Lai ST, Hsieh YC, Shih CC. Correlation between body mass index and leucopenia after administration of valganciclovir for cytomegalovirus infection in Chinese cardiac recipients. Circ. J.<\/i>, 71<\/b>, 968\u2013972 (2007).","DOI":"10.1253\/circj.71.968"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/4\/45_b21-00860\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T05:52:57Z","timestamp":1648878777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/45\/4\/45_b21-00860\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00860","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"article-number":"b21-00860"}}